Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAMBO II: Sumatriptan vs Rimegepant During Nitroglycerin-Induced Migraine
2024-519770-38-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rimegepant and sumatriptan in migraine (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Temporal evolution of GRP, AMY, VIP, and PACAP-38 levels in blood. Planned start Apr 2025; status: authorised.
02
Drugs
rimegepantsumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-519770-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519770-38-00.